Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum toxin type A for drooling and quality of life in cerebral palsy
IRCT20220516054868N1Phase 2Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Jun 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of botulinum toxin type A in cerebral palsy (CP) and hypersalivation, sponsored by Isfahan University of Medical Sciences. Primary endpoints: Reduction in salivation and Quality of life. Started Jun 2022; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
cerebral palsy (CP)hypersalivation
Beyond the preview
Go deeper on IRCT20220516054868N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20220516054868N1.